Brazilian academy of rhinology position paper on topical intranasal therapy

de Mello Júnior, João Ferreira; de Godoy Mion, Olavo; de Andrade, Nilvano Alves; Anselmo-Lima, Wilma Terezinha; Stamm, Aldo Eden Cassol; de Cerqueira Almeida, Washingthon Luiz; Filho, Pedro Oliveira Cavalcante; de Carvalho e Castro, Jair; de Melo Padua, Francini Grecco; Romano, Fabrizio Ricci; de Paulo Santos, Rodrigo; Roitmann, Renato; Voegels, Richard Louis; Meirelles, Roberto Campos; Sá, Leonardo Conrado Barbosa; Moacyr, Moacyr Tabasnik; Santos, Marco Cesar Jorge dos; Guimarães, Roberto Eustáquio Santos

doi:10.5935/1808-8694.20130120

Brazilian Journal of Otorhinolaryngology (English Edition)

ISSN: 1808-8694

The Brazilian Journal of Otorhinolaryngology aims to provide timely information for physicians and scientists focused on otorhinolaryngology and head and neck disorders, including contemporary, ethical, clinically relevant information in:

- General otolaryngology;
- Head and neck surgery;
- Respiratory sleep disorders;
- Allergy/rhinology;
- Otology/neurotology;
- Laryngology/broncho-esophagology;
- Pediatric otolaryngology;
- Cranio-facial surgery;
- Skull base surgery;
- Head and neck oncology;
- Phoniatrics;
- Upper airway related diseases;
- Facial plastics and reconstructive surgery.

The journal is the official peer-reviewed open access scientific publication of the Brazilian Association of Otorhinolaryngology and Cervicofacial Surgery (ABORL-CCF).

All articles will be published under the CC-BY license (Creative Commons Attribution 4.0 International) with copyright owned by the ABORL-CCF.

Please note that articles submitted as of May 1, 2022, which are accepted for publication will be subject to a fee (Article Publishing Charge, APC) payment by the author or research funder to cover the costs associated with publication.

Indexed in:

MEDLINE/PubMed, Scopus, Web of Science/SCIE, DOAJ, Lilacs, SciELO, Qualis A3

João Ferreira de Mello Júnior, Olavo de Godoy Mion, Nilvano Alves de Andrade, Wilma Terezinha Anselmo-Lima, Aldo Eden Cassol Stamm, Washingthon Luiz de Cerqueira Almeida, Pedro Oliveira Cavalcante Filho, Jair de Carvalho e Castro, Francini Grecco de Melo Padua, Fabrizio Ricci Romano, Rodrigo de Paulo Santos, Renato Roitmann, Richard Louis Voegels, Roberto Campos Meirelles, Leonardo Conrado Barbosa Sá, Moacyr Tabasnik Moacyr, Marco Cesar Jorge dos Santos, Roberto Eustáquio Santos Guimarães

This item has received

4681 Visits

Under a Creative Commons license

Article information

Full Text

Download PDF

Statistics

Tables (1)

Table 1. General characteristics of intranasal steroid formulations, age from which it can be used in allergic rhinitis and the corresponding doses for children and adults.

Full Text

On the lines corresponding to the fluticasone propionate and furoate, the data concerning age and dose are the following:

Table 1.

General characteristics of intranasal steroid formulations, age from which it can be used in allergic rhinitis and the corresponding doses for children and adults.

Name	Formulation	Minimum age	Dose per spray mcg*/nostril	Maximum dose/children mcg/day	Dose/adult mcg/day	Maximum dose for rhinitis and polyps ** mcg/day
Triamcinolone acetonide	Isotonic	4 years	55	110	220	220
Budesonide	Isotonic	6 years	32, 50, 64, 100	100	200	400
Ciclesonide	Hypotonic	6 years	50	100	200	400
Beclomethasone dipropionate	Isotonic	6 years	50	100	200	400
Mometasone furoate	Isotonic	2 years	50	100	200	400
Fluticasone propionate	Isotonic	4 years	50	100	200	400
Fluticasone furoate	Isotonic	2 years	27.5	55	110	220

mcg = micrograms.

To the present time there is no standardized dose for nasal polyps, only clinical trials, usually with the maximum drug dose3.

Source: Medications' inserts.

Indexed in:

Follow us:

Subscribe to our newsletter